A practical review on carfilzomib in multiple myeloma. (9th March 2016)

• Record Type: Journal Article
• Authors: Muchtar, Eli; Gertz, Morie A.; Magen, Hila
• Is Part Of: European journal of haematology. Volume 96:Number 6(2016:Jun.)
• Page Start: 564
• Page End: 577
• Publication Date: 2016-03-09
• Subjects: multiple myeloma -- relapse -- induction -- carfilzomib -- proteasome inhibitors -- combination regimen; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Blood -- Periodicals; 616.15005
• DOI: 10.1111/ejh.12749
• Languages: English
• ISSNs: 0902-4441

Abstract

Abstract: Carfilzomib, a second‐generation proteasome inhibitor, has been increasingly used in relapsed/refractory multiple myeloma (MM) since its approval by the American food and drug administration (FDA) in the summer of 2012. The drug is active as a single agent and in combination with other antimyeloma agents. As a result of its efficacy and safety in the relapsed/refractory setting, carfilzomib is being evaluated in patients with newly diagnosed MM as well as in high‐risk smoldering MM. This review will give a comprehensive summary of the drug, including its mechanism of action, the evaluated doses and schedules as well as a summary of the main clinical trials in the relapsed/refractory and newly diagnosed settings. A focus will be placed upon certain subgroups of interest as well as a description of the toxicity associated with carfilzomib use and a clinical perspective on toxicity management.